4basebio (LON:4BB) Stock Price Up 2% - Time to Buy?

4basebio PLC (LON:4BB - Get Free Report) was up 2% during trading on Tuesday . The company traded as high as GBX 1,150 ($15.57) and last traded at GBX 1,147 ($15.53). Approximately 146 shares traded hands during trading, a decline of 85% from the average daily volume of 978 shares. The stock had previously closed at GBX 1,125 ($15.23).

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada reissued an "outperform" rating and set a GBX 1,600 ($21.66) target price on shares of 4basebio in a research report on Thursday, March 13th.

4basebio Stock Down 2.2%

The firm has a market cap of £140.97 million, a PE ratio of -1,410.90 and a beta of 1.09. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The business's 50-day simple moving average is GBX 1,134.50 and its 200 day simple moving average is GBX 1,177.67.

Insider Activity

In other news, insider Amy Walker purchased 1,151 shares of the stock in a transaction dated Friday, February 28th. The shares were acquired at an average cost of GBX 1,120 ($15.16) per share, for a total transaction of £12,891.20 ($17,451.20). Also, insider Heikki Lanckriet purchased 2,400 shares of the stock in a transaction dated Wednesday, April 2nd. The stock was purchased at an average price of GBX 1,205 ($16.31) per share, for a total transaction of £28,920 ($39,149.86). Company insiders own 68.44% of the company's stock.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.